NewLink Genetics Corporation (NLNK) Stock Price Increases Today

April 17, 2018 - By Henry Gaston

NewLink Genetics Corporation (NASDAQ:NLNK) Logo

Investors sentiment increased to 1.51 in Q4 2017. Its up 0.29, from 1.22 in 2017Q3. It improved, as 22 investors sold NewLink Genetics Corporation shares while 21 reduced holdings. 28 funds opened positions while 37 raised stakes. 23.56 million shares or 27.79% more from 18.44 million shares in 2017Q3 were reported.
1,026 are held by Royal Savings Bank Of Canada. Meeder Asset Mgmt invested in 125 shares. Vanguard Gru owns 1.31 million shares or 0% of their US portfolio. Atlantic Tru Group Ltd Liability holds 200 shares or 0% of its portfolio. State Of Wisconsin Board owns 17,000 shares or 0% of their US portfolio. Pacad Investment owns 1,700 shares. Venbio Select Advisor Ltd Liability Co, a California-based fund reported 795,412 shares. Jpmorgan Chase And has invested 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Dimensional Fund Lp has 53,808 shares for 0% of their portfolio. California Pub Employees Retirement owns 18,300 shares. Moreover, Morgan Stanley has 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK) for 73,613 shares. Baldwin Investment Management Lc has 17,000 shares. Clarivest Asset Mngmt Lc invested in 74,400 shares or 0.01% of the stock. Gp One Trading L P holds 0% or 15,609 shares in its portfolio. Proshare Advisors Ltd Liability Com holds 24,286 shares.

The stock of NewLink Genetics Corporation (NASDAQ:NLNK) is a huge mover today! The stock increased 10.79% or $0.445 during the last trading session, reaching $4.57. About 1.44 million shares traded or 26.75% up from the average. NewLink Genetics Corporation (NASDAQ:NLNK) has declined 65.28% since April 17, 2017 and is downtrending. It has underperformed by 76.83% the S&P500.
The move comes after 5 months positive chart setup for the $169.80 million company. It was reported on Apr, 17 by Barchart.com. We have $4.94 PT which if reached, will make NASDAQ:NLNK worth $13.58 million more.

Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on May, 3. They expect $-0.55 earnings per share, up 23.61 % or $0.17 from last year’s $-0.72 per share. After $-0.37 actual earnings per share reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 48.65 % negative EPS growth.

NewLink Genetics Corporation (NASDAQ:NLNK) Ratings Coverage

Among 5 analysts covering NewLink Genetics (NASDAQ:NLNK), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. NewLink Genetics had 7 analyst reports since November 3, 2017 according to SRatingsIntel. SunTrust downgraded the stock to “Hold” rating in Monday, April 9 report. As per Friday, March 2, the company rating was maintained by Bank of America. The rating was downgraded by Bank of America to “Hold” on Friday, April 6. On Friday, April 6 the stock rating was downgraded by Jefferies to “Hold”. The firm has “Neutral” rating given on Monday, April 9 by Cantor Fitzgerald. On Monday, April 9 the stock rating was downgraded by Robert W. Baird to “Neutral”. The rating was maintained by Jefferies on Friday, November 3 with “Buy”.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $169.80 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: